Blueprint Medicines Corporation

NasdaqGS:BPMC Stock Report

Market Cap: US$5.7b

Blueprint Medicines Balance Sheet Health

Financial Health criteria checks 4/6

Blueprint Medicines has a total shareholder equity of $313.1M and total debt of $647.8M, which brings its debt-to-equity ratio to 206.9%. Its total assets and total liabilities are $1.2B and $886.5M respectively.

Key information

206.9%

Debt to equity ratio

US$647.78m

Debt

Interest coverage ration/a
CashUS$734.17m
EquityUS$313.15m
Total liabilitiesUS$886.50m
Total assetsUS$1.20b

Recent financial health updates

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Nov 24
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Aug 16
Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Apr 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Recent updates

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Nov 24
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Blueprint Medicines: Growth For The Long Term Still Mostly Priced In

Sep 27

Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Aug 16
Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S

Jul 23
Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S

Blueprint Medicines: Overdue For A Breather

Jul 16

Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 05
Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Blueprint Medicines: Rampant Growth Mostly Priced In

May 04

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Apr 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)

Apr 05
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

Feb 20

Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Jan 08
Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal

Sep 15

Blueprint to seek label expansion for systemic mastocytosis therapy after trial win

Aug 17

Financial Position Analysis

Short Term Liabilities: BPMC's short term assets ($854.8M) exceed its short term liabilities ($257.7M).

Long Term Liabilities: BPMC's short term assets ($854.8M) exceed its long term liabilities ($628.8M).

Debt to Equity History and Analysis

Debt Level: BPMC has more cash than its total debt.

Reducing Debt: BPMC's debt to equity ratio has increased from 0% to 206.9% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BPMC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BPMC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 15:51
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Blueprint Medicines Corporation is covered by 32 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Ishan MajumdarBaptista Research
Peter LawsonBarclays